News Summary

• “The team delivered another successful year, generating strong operating results in 2025 by serving more patients and introducing new services for Canadian patients,” said Joe Walewicz, NeuPath’s Chief Executive Officer.
• “We expect to deliver continued growth and margin improvement in 2026, as we serve more patients, expand to new locations, and broaden the availability of innovative procedures such as Arthrosamid®”(1)IFRS Accounting Standards (“IFRS” and Other Financial Measures defined by the Company below.